Bedrijfsoverzicht
Autonomix Medical, Inc. operates as a development stage medical device company dedicated to advancing technologies designed for sensing and treating disorders associated with the peripheral nervous system. The firm utilizes a technology platform that incorporates a catheter-based microchip-enabled sensing array to detect and differentiate specific physiological signals. This entity functions within the Healthcare sector, specifically targeting the Medical Devices industry, which implies a focus on innovation, regulatory compliance, and high-research environments rather than immediate mass manufacturing. The company currently maintains a market capitalization of $4.34M and employs 8 individuals to support its operational and research activities. These valuation and headcount figures indicate that the business is in an early-stage growth phase, where capital allocation prioritizes research and development over profit generation, resulting in a small market footprint relative to established industry peers. The absence of reported annual revenue in the available data further underscores the company's status as a pre-revenue or early-commercialization entity where market traction is yet to be fully realized in financial statements.
Financiële gezondheid
The financial statements for Autonomix Medical, Inc. report a Net Income of $-17,240,000 and an EBITDA of $-17,492,000 over the trailing twelve months, while the Revenue (TTM) is listed as N/A. The significant gap between revenue and net income, compounded by the lack of reported revenue, reveals a cost structure dominated by high operating expenses typical of development-stage firms, where research, personnel, and facility costs exceed any current sales income. The company reports a Free Cash Flow of $-5,933,875, indicating a substantial cash outflow that necessitates external financing or the use of existing cash reserves to sustain operations. This negative free cash flow suggests limited financial flexibility for short-term investments or acquisitions until commercial milestones are achieved and revenue streams materialize. All three reported margin metrics—Gross Margin, Operating Margin, and Profit Margin—are 0.0%, reflecting that the company has not yet generated sufficient gross profit to cover its operating costs or arrive at a net profit. Regarding liquidity and leverage, the company holds $9.93M in cash against $0 in debt, creating a strong cash position that mitigates solvency risks despite the negative earnings. The absence of debt results in a N/A debt-to-equity ratio, confirming a conservative balance sheet structure with no financial leverage applied to the equity base. Short-term liquidity is robust, evidenced by a Current Ratio of 6.18, which indicates the firm possesses more than six times the current assets required to cover its current liabilities. Return on Equity stands at -188.7% and Return on Assets at -99.0%, metrics that reveal the company is currently burning capital rather than generating returns, a common characteristic for firms in the initial phases of product development.
Waarderingsbeoordeling
Valuation metrics for Autonomix Medical, Inc. present a complex picture due to the lack of profitability, with a Trailing P/E Ratio (TTM) listed as N/A and a Forward P/E of -0.05. The negative forward P/E ratio implies that the market is pricing in expectations of continued losses or that standard earnings-based valuation models are not applicable given the company's current operational stage. The Price to Book ratio is 0.51, suggesting the company's market capitalization trades at a discount to its book value, which can occur in distressed situations or in speculative growth companies where intangible assets and future potential are not fully captured on the balance sheet. Since Revenue is N/A, the Price to Sales ratio is also N/A, meaning traditional sales-based valuation multiples cannot be calculated; however, the EV/EBITDA stands at 0.32, an extremely low figure that typically indicates deep undervaluation or, in this context, a lack of positive earnings to support a standard multiple. The stock has traded between a 52-Week High of $2.82 and a 52-Week Low of $0.34, highlighting significant price volatility over the past year. The Beta value is -2.46, a highly unusual and negative figure that indicates the stock's price moves inversely to the broader market with high intensity, suggesting extreme sensitivity to market sentiment or specific sector factors rather than standard correlation.
Growth & Income
The available financial data lists Revenue Growth (YoY) and Earnings Growth (YoY) as N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue in a quantitative sense. In the absence of a dividend yield and payout ratio, which are both N/A or 0.0%, the company clearly does not distribute income to shareholders, a strategy consistent with development-stage entities that must reinvest all available resources, including the $9.93M cash on hand, into research and development to achieve product milestones. The 0.0% payout ratio confirms that the entire net loss is being retained within the company to fund operations rather than being distributed to investors. Consequently, the overall growth and income profile of Autonomix Medical, Inc. is characterized by a focus on capital preservation and R&D expenditure rather than shareholder returns or revenue expansion metrics that are currently unquantifiable due to the N/A revenue figures.